Valerie Uytterhoeven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valerie Uytterhoeven has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Patrik Verstreken
VIB-KU Leuven Center for Brain & Disease Research, 3000 Leuven, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, 3000 Leuven, Belgium
8 shared publications Jef Swerts
VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium; KU Leuven, Department of Neurosciences, Leuven Brain Institute, Mission Lucidity, Leuven, Belgium
4 shared publicationsSabine Kuenen
VIB Center for Brain &Disease Research, Leuven, Belgium
4 shared publications- Eliana Nachman
VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium
3 shared publications Patrik Verstreken
Leuven Brain Institute, KU-Leuven, Leuven, Belgium
3 shared publications- Abril Escamilla-Ayala
KU Leuven
2 shared publications
Latest Publications
- Open Access
- 21 August 2025
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (20) , 5662-5693
Soma-localized Rab39 inhibits synaptic autophagy by controlling trafficking of Atg9 vesicles
Presynaptic terminals can be located far from the neuronal cell body and are thought to independently regulate protein and organelle turnover. Autophagy is a critical process for maintaining proteostasis, and its synaptic dysregulation is associated with neurodegenerative diseases. In this work, we report a soma-centered mechanism that regulates autophagy-controlled protein turnover at distant presynaptic terminals in Drosophila . We show that a central component of this system is Rab39, whose human homolog RAB39B is mutated in Parkinson’s disease. Although Rab39 is localized in the soma, its loss of function or a human pathogenic mutation causes increased autophagy at presynaptic terminals, resulting in faster synaptic protein turnover and dopaminergic synapse degeneration. Using a large-scale unbiased genetic modifier screen, we identified genes encoding cytoskeletal and axonal organizing proteins, including Shortstop (Shot), as suppressors of synaptic autophagy. We demonstrate that active Rab39 selectively controls Shot- and Unc104/KIF1A-mediated delivery of autophagy-related Atg9-positive vesicles to synapses. Our findings suggest that Rab39-mediated trafficking in the soma orchestrates a cross-compartmental mechanism that regulates the levels of autophagy at synapses.
- 21 August 2025
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (20) , 5662-5693
Open AccessSoma-localized Rab39 inhibits synaptic autophagy by controlling trafficking of Atg9 vesicles
Presynaptic terminals can be located far from the neuronal cell body and are thought to independently regulate protein and organelle turnover. Autophagy is a critical process for maintaining proteostasis, and its synaptic dysregulation is associated with neurodegenerative diseases. In this work, we report a soma-centered mechanism that regulates autophagy-controlled protein turnover at distant presynaptic terminals in Drosophila . We show that a central component of this system is Rab39, whose human homolog RAB39B is mutated in Parkinson’s disease. Although Rab39 is localized in the soma, its loss of function or a human pathogenic mutation causes increased autophagy at presynaptic terminals, resulting in faster synaptic protein turnover and dopaminergic synapse degeneration. Using a large-scale unbiased genetic modifier screen, we identified genes encoding cytoskeletal and axonal organizing proteins, including Shortstop (Shot), as suppressors of synaptic autophagy. We demonstrate that active Rab39 selectively controls Shot- and Unc104/KIF1A-mediated delivery of autophagy-related Atg9-positive vesicles to synapses. Our findings suggest that Rab39-mediated trafficking in the soma orchestrates a cross-compartmental mechanism that regulates the levels of autophagy at synapses.
- 24 December 2024
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (2)
Synaptic sabotage: How Tau and α-Synuclein undermine synaptic health
Synaptic dysfunction is one of the earliest cellular defects observed in Alzheimer’s disease (AD) and Parkinson’s disease (PD), occurring before widespread protein aggregation, neuronal loss, and cognitive decline. While the field has focused on the aggregation of Tau and α-Synuclein (α-Syn), emerging evidence suggests that these proteins may drive presynaptic pathology even before their aggregation. Therefore, understanding the mechanisms by which Tau and α-Syn affect presynaptic terminals offers an opportunity for developing innovative therapeutics aimed at preserving synapses and potentially halting neurodegeneration. This review focuses on the molecular defects that converge on presynaptic dysfunction caused by Tau and α-Syn. Both proteins have physiological roles in synapses. However, during disease, they acquire abnormal functions due to aberrant interactions and mislocalization. We provide an overview of current research on different essential presynaptic pathways influenced by Tau and α-Syn. Finally, we highlight promising therapeutic targets aimed at maintaining synaptic function in both tauopathies and synucleinopathies.
- 24 December 2024
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (2)
Synaptic sabotage: How Tau and α-Synuclein undermine synaptic health
Synaptic dysfunction is one of the earliest cellular defects observed in Alzheimer’s disease (AD) and Parkinson’s disease (PD), occurring before widespread protein aggregation, neuronal loss, and cognitive decline. While the field has focused on the aggregation of Tau and α-Synuclein (α-Syn), emerging evidence suggests that these proteins may drive presynaptic pathology even before their aggregation. Therefore, understanding the mechanisms by which Tau and α-Syn affect presynaptic terminals offers an opportunity for developing innovative therapeutics aimed at preserving synapses and potentially halting neurodegeneration. This review focuses on the molecular defects that converge on presynaptic dysfunction caused by Tau and α-Syn. Both proteins have physiological roles in synapses. However, during disease, they acquire abnormal functions due to aberrant interactions and mislocalization. We provide an overview of current research on different essential presynaptic pathways influenced by Tau and α-Syn. Finally, we highlight promising therapeutic targets aimed at maintaining synaptic function in both tauopathies and synucleinopathies.
- Open Access
Soma-centered control of synaptic autophagy by Rab39-regulated anterograde trafficking of Atg9
Presynaptic terminals can be located far from the neuronal cell body and are thought to independently regulate protein and organelle turnover. In this work, we report a soma-centered mechanism that regulates autophagy-driven protein turnover at distant presynaptic terminals in Drosophila . We show that this system is regulated by Rab39, whose human homolog is mutated in Parkinson’s disease. Although Rab39 is localized in the soma, its loss of function causes increased autophagy at presynaptic terminals, resulting in faster synaptic protein turnover and neurodegeneration. Using a large-scale unbiased genetic modifier screen, we identified genes encoding cytoskeletal and axonal organizing proteins, including Shortstop ( Shot ), as suppressors of synaptic autophagy. We demonstrate that Rab39 controls Shot-and Unc104/KIF1a-mediated transport of autophagy-related Atg9 vesicles to synapses. Under starvation conditions, Rab39 in the soma shifts its localization from endosomes to lysosomes, thereby controlling the availability of Atg9 vesicles for trafficking to synapses. Our findings indicate that Rab39-mediated trafficking in the soma orchestrates a cross-compartmental mechanism that regulates the abundance of autophagy at synapses.
Open AccessSoma-centered control of synaptic autophagy by Rab39-regulated anterograde trafficking of Atg9
Presynaptic terminals can be located far from the neuronal cell body and are thought to independently regulate protein and organelle turnover. In this work, we report a soma-centered mechanism that regulates autophagy-driven protein turnover at distant presynaptic terminals in Drosophila . We show that this system is regulated by Rab39, whose human homolog is mutated in Parkinson’s disease. Although Rab39 is localized in the soma, its loss of function causes increased autophagy at presynaptic terminals, resulting in faster synaptic protein turnover and neurodegeneration. Using a large-scale unbiased genetic modifier screen, we identified genes encoding cytoskeletal and axonal organizing proteins, including Shortstop ( Shot ), as suppressors of synaptic autophagy. We demonstrate that Rab39 controls Shot-and Unc104/KIF1a-mediated transport of autophagy-related Atg9 vesicles to synapses. Under starvation conditions, Rab39 in the soma shifts its localization from endosomes to lysosomes, thereby controlling the availability of Atg9 vesicles for trafficking to synapses. Our findings indicate that Rab39-mediated trafficking in the soma orchestrates a cross-compartmental mechanism that regulates the abundance of autophagy at synapses.
- 11 January 2021
- Published by Springer Nature in Acta Neuropathologica
- Vol. 141 (2) , 173-192
Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation
In Alzheimer’s disease (AD), tau-protein undergoes a multi-step process involving the transition from a natively unfolded monomer to large, aggregated structures such as neurofibrillary tangles (NFTs). However, it is not yet clear which events initiate the early preclinical phase of AD tauopathy and whether they have impact on the propagation of tau pathology in later disease stages. To address this question, we analyzed the distribution of tau species phosphorylated at T231, S396/S404 and S202/T205, conformationally modified at the MC1 epitope and fibrillary tau detected by the Gallyas method (Gallyas-tau), in the brains of 15 symptomatic and 20 asymptomatic cases with AD pathology as well as of 19 nonAD cases. As initial tau lesions, we identified phosphorylated-T231-tau diffusely distributed within the somatodendritic compartment (IC-tau) and phosphorylated-S396/pS404-tau in axonal lesions of the white matter and in the neuropil (IN-tau). The subcellular localization of pT231-tau in the cell body and pS396/pS404-tau in the presynapse was confirmed in hP301L mutant Drosophila larvae. Phosphorylated-S202/T205-tau, MC1-tau and Gallyas-tau were negative for these lesions. IC- and IN-tau were observed in all analyzed regions of the human brain, including early affected regions in nonAD cases (entorhinal cortex) and late affected regions in symptomatic AD cases (cerebellum), indicating that tau pathology initiation follows similar processes when propagating into previously unaffected regions. Furthermore, a sequence of AD-related maturation of tau-aggregates was observed, initiated by the appearance of IC- and IN-tau, followed by the formation of pretangles exhibiting pT231-tau, pS396/pS404-tau and pS202/pT205-tau, then by MC1-conformational tau, and, finally, by the formation of Gallyas-positive NFTs. Since cases classified as nonAD [Braak NFT stages < I (including a-1b)] already showed IC- and IN-tau, our findings suggest that these lesions are a prerequisite for the development of AD.
- 11 January 2021
- Published by Springer Nature in Acta Neuropathologica
- Vol. 141 (2) , 173-192
Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation
In Alzheimer’s disease (AD), tau-protein undergoes a multi-step process involving the transition from a natively unfolded monomer to large, aggregated structures such as neurofibrillary tangles (NFTs). However, it is not yet clear which events initiate the early preclinical phase of AD tauopathy and whether they have impact on the propagation of tau pathology in later disease stages. To address this question, we analyzed the distribution of tau species phosphorylated at T231, S396/S404 and S202/T205, conformationally modified at the MC1 epitope and fibrillary tau detected by the Gallyas method (Gallyas-tau), in the brains of 15 symptomatic and 20 asymptomatic cases with AD pathology as well as of 19 nonAD cases. As initial tau lesions, we identified phosphorylated-T231-tau diffusely distributed within the somatodendritic compartment (IC-tau) and phosphorylated-S396/pS404-tau in axonal lesions of the white matter and in the neuropil (IN-tau). The subcellular localization of pT231-tau in the cell body and pS396/pS404-tau in the presynapse was confirmed in hP301L mutant Drosophila larvae. Phosphorylated-S202/T205-tau, MC1-tau and Gallyas-tau were negative for these lesions. IC- and IN-tau were observed in all analyzed regions of the human brain, including early affected regions in nonAD cases (entorhinal cortex) and late affected regions in symptomatic AD cases (cerebellum), indicating that tau pathology initiation follows similar processes when propagating into previously unaffected regions. Furthermore, a sequence of AD-related maturation of tau-aggregates was observed, initiated by the appearance of IC- and IN-tau, followed by the formation of pretangles exhibiting pT231-tau, pS396/pS404-tau and pS202/pT205-tau, then by MC1-conformational tau, and, finally, by the formation of Gallyas-positive NFTs. Since cases classified as nonAD [Braak NFT stages < I (including a-1b)] already showed IC- and IN-tau, our findings suggest that these lesions are a prerequisite for the development of AD.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S3)
Increased HSC70‐4/HSPA8 regulated autophagy reduces tau‐mediated synaptic dysfunction
Background: Tau tangles are present in the brains of Alzheimer diseased (AD) patients and strategies that remove Tau oligomers and Tau tangles are tested in clinical trials. These anti‐Tau drugs may keep misfolded Tau from spreading and damaging additional neurons, but they may be inefficient at targeting soluble Tau early in the disease before tangles are formed and thus be relatively late to spare cognitive defects. Our research is therefore refreshing as it may tackle early Tau induced dysfunction. We have shown in Drosophila that the overexpression of the chaperone Hsc70‐4 promotes endosomal microautophagy at presynapses and regulates the turnover of synaptic proteins harboring pentapeptide motifs, biochemically related to the KFERQ sequence (Uytterhoeven, 2015). Intriguingly, Tau harbors two such motifs.Method: We tested if increasing endosomal microautophagy by overexpressing Hsc70‐4 has an effect on Tau‐mediated synaptic defects .Result: Indeed, increasing microautophagy reduces presynaptic Tau levels and presynaptic vesicle sequestrations at presynapses, two phenotypes previously shown by our lab to appear after expressing pathogenic Tau in the fly nervous system (Zhou, 2017 and McInnes, 2018). In addition, via lentiviral‐mediated overexpression of HSPA8, the human homologue of Hsc70‐4, we are able to increase HSPA8 regulated autophagy in human neurons.Conclusion: Together, our work provides important molecular insight into the contribution of Hsc70‐4/HSPA8 regulated autophagy on AD disease onset and progression and may contribute to the development of methods and treatments to alleviate the defects in dementia.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S3)
Increased HSC70‐4/HSPA8 regulated autophagy reduces tau‐mediated synaptic dysfunction
Background: Tau tangles are present in the brains of Alzheimer diseased (AD) patients and strategies that remove Tau oligomers and Tau tangles are tested in clinical trials. These anti‐Tau drugs may keep misfolded Tau from spreading and damaging additional neurons, but they may be inefficient at targeting soluble Tau early in the disease before tangles are formed and thus be relatively late to spare cognitive defects. Our research is therefore refreshing as it may tackle early Tau induced dysfunction. We have shown in Drosophila that the overexpression of the chaperone Hsc70‐4 promotes endosomal microautophagy at presynapses and regulates the turnover of synaptic proteins harboring pentapeptide motifs, biochemically related to the KFERQ sequence (Uytterhoeven, 2015). Intriguingly, Tau harbors two such motifs.Method: We tested if increasing endosomal microautophagy by overexpressing Hsc70‐4 has an effect on Tau‐mediated synaptic defects .Result: Indeed, increasing microautophagy reduces presynaptic Tau levels and presynaptic vesicle sequestrations at presynapses, two phenotypes previously shown by our lab to appear after expressing pathogenic Tau in the fly nervous system (Zhou, 2017 and McInnes, 2018). In addition, via lentiviral‐mediated overexpression of HSPA8, the human homologue of Hsc70‐4, we are able to increase HSPA8 regulated autophagy in human neurons.Conclusion: Together, our work provides important molecular insight into the contribution of Hsc70‐4/HSPA8 regulated autophagy on AD disease onset and progression and may contribute to the development of methods and treatments to alleviate the defects in dementia.
- Open Access
- 1 January 2018
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 12
Increased endosomal microautophagy reduces Tau driven synaptic dysfunction.
Valerie Uytterhoeven, Liesbeth Deaulmerie, Patrik Verstreken VIB-KU Leuven Center for Brain and Disease Research 3000, Leuven, Belgium Most of the drug discovery efforts in AD have been focused on Aß removal but these studies have been unsuccessful in phase 3 clinical trials. Therefore, there is an urgent need to fill the therapeutic pipeline with new innovative targets in dementia. Targeting Tau is emerging as a new and exciting possibility as Tau is a major mediator of neurodegeneration. Tau tangles are present in the brains of AD patients but also several other neurodegenerative diseases and strategies that remove Tau oligomers and Tau tangles are tested in clinical trials. These anti-Tau drugs may keep misfolded Tau from spreading and damaging additional neurons, but they may be inefficient at targeting soluble Tau early in the disease before tangles are formed and thus be relatively late to spare cognitive defects. Our approach is therefore refreshing as it tackles a different aspect of Tau induced dysfunction. We have shown in Drosophila that endosomal microautophagy is functional at presynapses and regulates the turnover of proteins harboring pentapeptide motifs, biochemically related to the KFERQ sequence. The chaperone, Hsc70-4 recognizes proteins with such a motif and regulates their turnover by the engulfment of these proteins in the multivesicular bodies/late endosomes via inducing membrane bending (Uytterhoeven, 2015). Intriguingly, Tau harbors two such motifs and we tested if increasing Hsc70 levels has an effect on Tau levels and its pathogenic function. Indeed, increasing microautophagy reduces mutant Tau levels and synaptic vesicles sequestration at the presynapse, two phenotypes previously shown by our lab to appear after expressing mutant Tau in the nervous system of the fly (Zhou et al. ,2017 and McInnes et al., 2018). We will further test if increasing microautophagy levels is able to rescue Tau associated neurodegeneration in the fly brain. In addition, we are generating tools to increase microautophagy levels in human neurons and test the effect on Tau pathology of human neurons harboring pathogenic Tau mutations. Together, our work provides important insight into the contribution of microautophagy on Tau-induced disease onset and progression and the knowledge of these molecular mechanisms allows the development of methods/treatments to alleviate defects in dementia.
- 1 January 2018
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 12
Open AccessIncreased endosomal microautophagy reduces Tau driven synaptic dysfunction.
Valerie Uytterhoeven, Liesbeth Deaulmerie, Patrik Verstreken VIB-KU Leuven Center for Brain and Disease Research 3000, Leuven, Belgium Most of the drug discovery efforts in AD have been focused on Aß removal but these studies have been unsuccessful in phase 3 clinical trials. Therefore, there is an urgent need to fill the therapeutic pipeline with new innovative targets in dementia. Targeting Tau is emerging as a new and exciting possibility as Tau is a major mediator of neurodegeneration. Tau tangles are present in the brains of AD patients but also several other neurodegenerative diseases and strategies that remove Tau oligomers and Tau tangles are tested in clinical trials. These anti-Tau drugs may keep misfolded Tau from spreading and damaging additional neurons, but they may be inefficient at targeting soluble Tau early in the disease before tangles are formed and thus be relatively late to spare cognitive defects. Our approach is therefore refreshing as it tackles a different aspect of Tau induced dysfunction. We have shown in Drosophila that endosomal microautophagy is functional at presynapses and regulates the turnover of proteins harboring pentapeptide motifs, biochemically related to the KFERQ sequence. The chaperone, Hsc70-4 recognizes proteins with such a motif and regulates their turnover by the engulfment of these proteins in the multivesicular bodies/late endosomes via inducing membrane bending (Uytterhoeven, 2015). Intriguingly, Tau harbors two such motifs and we tested if increasing Hsc70 levels has an effect on Tau levels and its pathogenic function. Indeed, increasing microautophagy reduces mutant Tau levels and synaptic vesicles sequestration at the presynapse, two phenotypes previously shown by our lab to appear after expressing mutant Tau in the nervous system of the fly (Zhou et al. ,2017 and McInnes et al., 2018). We will further test if increasing microautophagy levels is able to rescue Tau associated neurodegeneration in the fly brain. In addition, we are generating tools to increase microautophagy levels in human neurons and test the effect on Tau pathology of human neurons harboring pathogenic Tau mutations. Together, our work provides important insight into the contribution of microautophagy on Tau-induced disease onset and progression and the knowledge of these molecular mechanisms allows the development of methods/treatments to alleviate defects in dementia.
- 26 September 2016
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 23 (11) , 965-973
Skywalker-TBC1D24 has a lipid-binding pocket mutated in epilepsy and required for synaptic function
Structural, biochemical and functional analyses elucidate the mechanisms by which mutations in the TBC1D24 gene interfere with protein function, thus causing early-onset epilepsy and DOORS syndrome.
- 26 September 2016
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 23 (11) , 965-973
Skywalker-TBC1D24 has a lipid-binding pocket mutated in epilepsy and required for synaptic function
Structural, biochemical and functional analyses elucidate the mechanisms by which mutations in the TBC1D24 gene interfere with protein function, thus causing early-onset epilepsy and DOORS syndrome.
- Open Access
- 24 November 2014
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 207 (4) , 453-462
Reduced synaptic vesicle protein degradation at lysosomes curbs TBC1D24/sky-induced neurodegeneration
Synaptic demise and accumulation of dysfunctional proteins are thought of as common features in neurodegeneration. However, the mechanisms by which synaptic proteins turn over remain elusive. In this paper, we study Drosophila melanogaster lacking active TBC1D24/Skywalker (Sky), a protein that in humans causes severe neurodegeneration, epilepsy, and DOOR (deafness, onychdystrophy, osteodystrophy, and mental retardation) syndrome, and identify endosome-to-lysosome trafficking as a mechanism for degradation of synaptic vesicle-associated proteins. In fly sky mutants, synaptic vesicles traveled excessively to endosomes. Using chimeric fluorescent timers, we show that synaptic vesicle-associated proteins were younger on average, suggesting that older proteins are more efficiently degraded. Using a genetic screen, we find that reducing endosomal-to-lysosomal trafficking, controlled by the homotypic fusion and vacuole protein sorting (HOPS) complex, rescued the neurotransmission and neurodegeneration defects in sky mutants. Consistently, synaptic vesicle proteins were older in HOPS complex mutants, and these mutants also showed reduced neurotransmission. Our findings define a mechanism in which synaptic transmission is facilitated by efficient protein turnover at lysosomes and identify a potential strategy to suppress defects arising from TBC1D24 mutations in humans.
- 24 November 2014
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 207 (4) , 453-462
Open AccessReduced synaptic vesicle protein degradation at lysosomes curbs TBC1D24/sky-induced neurodegeneration
Synaptic demise and accumulation of dysfunctional proteins are thought of as common features in neurodegeneration. However, the mechanisms by which synaptic proteins turn over remain elusive. In this paper, we study Drosophila melanogaster lacking active TBC1D24/Skywalker (Sky), a protein that in humans causes severe neurodegeneration, epilepsy, and DOOR (deafness, onychdystrophy, osteodystrophy, and mental retardation) syndrome, and identify endosome-to-lysosome trafficking as a mechanism for degradation of synaptic vesicle-associated proteins. In fly sky mutants, synaptic vesicles traveled excessively to endosomes. Using chimeric fluorescent timers, we show that synaptic vesicle-associated proteins were younger on average, suggesting that older proteins are more efficiently degraded. Using a genetic screen, we find that reducing endosomal-to-lysosomal trafficking, controlled by the homotypic fusion and vacuole protein sorting (HOPS) complex, rescued the neurotransmission and neurodegeneration defects in sky mutants. Consistently, synaptic vesicle proteins were older in HOPS complex mutants, and these mutants also showed reduced neurotransmission. Our findings define a mechanism in which synaptic transmission is facilitated by efficient protein turnover at lysosomes and identify a potential strategy to suppress defects arising from TBC1D24 mutations in humans.